<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215227</url>
  </required_header>
  <id_info>
    <org_study_id>P06153</org_study_id>
    <secondary_id>2009-015162-57</secondary_id>
    <nct_id>NCT01215227</nct_id>
  </id_info>
  <brief_title>An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)</brief_title>
  <official_title>A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Phase 3, Protocol No. P06153)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this extension study is to assess the long-term safety and
      tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and
      NCT01227265 [P07037] with moderate to severe Parkinson's Disease (PD). The study will also
      characterize the long-term efficacy of preladenant in participants with PD.

      Participants will continue to receive their stable regimen of levodopa (L-dopa) plus any
      adjunct medications during the study as prescribed by their physician. Several classes of
      adjunct medications may be used, including Amantadine, anticholinergics, dopa decarboxylase
      inhibitors, and dopamine agonists.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Systolic Blood Pressure ≥180 mmHg</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>The percentage of participants with Systolic Blood Pressure ≥180 mm Hg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Diastolic Blood Pressure ≥105 mmHg</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>The percentage of participants with Diastolic Blood Pressure ≥105 mmHg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>The number of participants with ALT ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Aspartate Aminotransferase (AST) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>The number of participants with AST ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Suicidality</measure>
    <time_frame>Up to 42 weeks</time_frame>
    <description>The number of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Total Epworth Sleepiness Scale (ESS) Score at Week 40</measure>
    <time_frame>Baseline and Week 40</time_frame>
    <description>The ESS is a self-administered questionnaire providing a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24 with a higher score indicating greater sleepiness.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">839</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Idiopathic Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 5 mg (on placebo in parent study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rasagiline 1 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rasagiline 1 mg (on placebo in parent study)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preladenant</intervention_name>
    <description>Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)</description>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_label>Preladenant 5 mg (on placebo in parent study)</arm_group_label>
    <arm_group_label>Preladenant 10 mg</arm_group_label>
    <other_name>SCH 420814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasagiline</intervention_name>
    <description>Daily for 40 weeks: 1 mg rasagiline capsule each morning</description>
    <arm_group_label>Rasagiline 1 mg</arm_group_label>
    <arm_group_label>Rasagiline 1 mg (on placebo in parent study)</arm_group_label>
    <other_name>Azilect®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to preladenant</intervention_name>
    <description>Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)</description>
    <arm_group_label>Rasagiline 1 mg</arm_group_label>
    <arm_group_label>Rasagiline 1 mg (on placebo in parent study)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to rasagiline</intervention_name>
    <description>Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning</description>
    <arm_group_label>Preladenant 2 mg</arm_group_label>
    <arm_group_label>Preladenant 5 mg</arm_group_label>
    <arm_group_label>Preladenant 5 mg (on placebo in parent study)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who have completed the 12-week treatment period of the parent trial,
             P04938 or P07037.

          -  Participants must be willing and able to provide written informed consent for P06153.

          -  Participants must be able to adhere to dose and visit schedules.

          -  Participants must be taking L-dopa.

          -  Participants may be taking additional adjunct PD medications (e.g., dopamine agonists,
             entacapone).

          -  Each participant must have results of clinical laboratory tests (hematology, blood
             chemistries, and urinalysis) within normal limits or clinically acceptable to the
             investigator as evidenced by the last available test results from the parent study
             (P04938 or P07037), and no results fall within the parameters for exclusion described
             below in the exclusion criterion for liver-related findings.

          -  There has been no change in, or there has been no finding to warrant checking,
             serology status (for cytomegalovirus [CMV], Epstein-Barr virus [EBV], and Hepatitis B,
             C, and E).

          -  Each participant must have results of a physical examination within normal limits,
             including blood pressure, within normal limits or clinically acceptable limits to the
             investigator, and not within the parameters for exclusion described below in the
             exclusion criterion for blood pressure.

          -  All participants who are sexually active or plan to be sexually active agree to use a
             highly effective method of birth control while the participant is in the study and for
             2 weeks after the last dose of study drug. A male participant must not donate sperm
             within 2 weeks after the last dose of study drug.

        Exclusion Criteria:

          -  Any participant who discontinued from P04938 or P07037 for any reason.

          -  Any participant with a severe or ongoing unstable medical condition (e.g., any form of
             clinically significant cardiac disease, symptomatic orthostatic hypotension, seizures,
             or alcohol/drug dependence).

          -  Any participant with a history of poorly controlled diabetes (e.g., hemoglobin A1c &gt;
             8.5) or significantly abnormal renal function (e.g., creatinine &gt; 2.0 mg/dL) in the
             opinion of the investigator.

          -  As a continuation of the liver-related withdrawal criteria from the parent studies
             (P04938 and P07037), any participant with elevated values for alanine aminotransferase
             (ALT), aspartate aminotransferase (AST), or total bilirubin (T BIL), as evidenced by
             the most recent chemistry panel results in the parent study, meeting any one of the
             following criteria:

          -  ALT or AST &gt; 8 x upper limit of normal (ULN).

          -  ALT or AST &gt; 5 x ULN for more than 2 weeks.

          -  ALT or AST &gt; 3 x ULN and (T-BIL &gt; 2 x ULN or international normalized ratio [INR] &gt;
             1.5 that is not due to anti-coagulation) at the same visit.

          -  ALT or AST &gt; 3 x ULN with the appearance of worsening fatigue, nausea, vomiting, right
             upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (&gt; 5%).

          -  As a continuation of the blood pressure (BP) withdrawal criteria from the parent study
             (P04938 or P07037), any participant meeting the following criteria for the second of
             two consecutive visits separated by 7 days (i.e., the participant met one of the BP
             criteria once already, 7 days before the P06153 screening visit):

          -  Systolic BP ≥ 180 mm Hg or diastolic BP ≥ 105 mm Hg, or

          -  An elevation from baseline BP in the parent study (P04938 or P07037) of systolic BP &gt;=
             40 mm Hg or diastolic BP ≥ 20 mm Hg.

          -  A participant must not have a history within the past 5 years of a primary or
             recurrent malignant disease with the exception of adequately treated basal cell or
             squamous cell skin cancer, in situ cervical cancer, or in situ prostate cancer with a
             normal prostate-specific antigen (PSA) post resection.

          -  Any participant with an average daily consumption of more than three 4-ounce glasses
             (118 mL) of wine or the equivalent.

          -  A participant must not have received certain prespecified medications or ingested high
             tyramine-containing aged cheeses (e.g., Stilton) for a prespecified time window before
             the trial, during the trial, and for 2 weeks after the trial.

          -  Any participant with allergy/sensitivity to the investigational products or their
             excipients.

          -  Any female participant breast feeding or considering breast feeding.

          -  Any female participant pregnant or intending to become pregnant.

          -  Any participant with any clinically significant condition or situation, other than the
             condition being studied that, in the opinion of the investigator, would interfere with
             the trial evaluations or optimal participation in the trial.

          -  Any participant with a member or a family member of the personnel of the
             investigational or sponsor staff directly involved with this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>October 18, 2016</results_first_submitted>
  <results_first_submitted_qc>October 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 12, 2016</results_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Preladenant 2 mg</title>
          <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Preladenant 5 mg</title>
          <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
          <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Preladenant 10 mg</title>
          <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Rasagiline 1 mg</title>
          <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
          <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="97"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="96"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="45"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="119"/>
                <participants group_id="P3" count="57"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance With Protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="24"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="40"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Participants as Treated: All participants who received at least one dose of study drug in Extension Study P06153. Data were not reported for 3 participants who were randomized but not treated.</population>
      <group_list>
        <group group_id="B1">
          <title>Preladenant 2 mg</title>
          <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Preladenant 5 mg</title>
          <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
          <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Preladenant 10 mg</title>
          <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Rasagiline 1 mg</title>
          <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
          <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="218"/>
            <count group_id="B2" value="215"/>
            <count group_id="B3" value="106"/>
            <count group_id="B4" value="96"/>
            <count group_id="B5" value="93"/>
            <count group_id="B6" value="108"/>
            <count group_id="B7" value="836"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="8.5"/>
                    <measurement group_id="B2" value="63.0" spread="8.7"/>
                    <measurement group_id="B3" value="64.4" spread="8.7"/>
                    <measurement group_id="B4" value="63.9" spread="8.0"/>
                    <measurement group_id="B5" value="63.8" spread="9.9"/>
                    <measurement group_id="B6" value="63.9" spread="7.8"/>
                    <measurement group_id="B7" value="63.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="41"/>
                    <measurement group_id="B7" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="67"/>
                    <measurement group_id="B7" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Systolic Blood Pressure ≥180 mmHg</title>
        <description>The percentage of participants with Systolic Blood Pressure ≥180 mm Hg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round).</description>
        <time_frame>Up to 42 weeks</time_frame>
        <population>All Participants as Treated (APaT) population, which consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Preladenant 10 mg</title>
            <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Systolic Blood Pressure ≥180 mmHg</title>
          <description>The percentage of participants with Systolic Blood Pressure ≥180 mm Hg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round).</description>
          <population>All Participants as Treated (APaT) population, which consisted of all participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.9"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Diastolic Blood Pressure ≥105 mmHg</title>
        <description>The percentage of participants with Diastolic Blood Pressure ≥105 mmHg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round).</description>
        <time_frame>Up to 42 weeks</time_frame>
        <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Preladenant 10 mg</title>
            <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Diastolic Blood Pressure ≥105 mmHg</title>
          <description>The percentage of participants with Diastolic Blood Pressure ≥105 mmHg was reported. On Day 1 and Early Termination, blood pressure was measured as follows: Participant lay supine for 5 minutes, then had blood pressure taken; then stood for 3 minutes and had blood pressure taken; then rested for 10 minutes, at which time the process was repeated twice (ie, three rounds total). For all other blood pressure measurements, the procedure needed only to be done once (ie, one round).</description>
          <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="5.7"/>
                    <measurement group_id="O4" value="5.2"/>
                    <measurement group_id="O5" value="7.5"/>
                    <measurement group_id="O6" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline</title>
        <description>The number of participants with ALT ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits.</description>
        <time_frame>Up to 42 weeks</time_frame>
        <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Preladenant 10 mg</title>
            <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline</title>
          <description>The number of participants with ALT ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits.</description>
          <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Aspartate Aminotransferase (AST) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline</title>
        <description>The number of participants with AST ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits.</description>
        <time_frame>Up to 42 weeks</time_frame>
        <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Preladenant 10 mg</title>
            <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Aspartate Aminotransferase (AST) ≥3 Times Upper Limit of Normal and ≥10% Increase From Baseline</title>
          <description>The number of participants with AST ≥3 times the upper limit of normal and a ≥10% increase was reported. Laboratory safety blood work was collected from participants at Week 4, Week 6, and Week 8 visits.</description>
          <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.1"/>
                    <measurement group_id="O5" value="1.1"/>
                    <measurement group_id="O6" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Suicidality</title>
        <description>The number of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.</description>
        <time_frame>Up to 42 weeks</time_frame>
        <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Preladenant 10 mg</title>
            <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suicidality</title>
          <description>The number of participants with suicidality using the Columbia - Suicide Severity Rating Scale (C-SSRS) was reported. The C-SSR was used in this study only for the purpose of safety monitoring by measuring the incidence of different types of suicidality categories during treatment. The assessment was done by the nature of the responses, not by a numbered scale. Participants who reported at least one occurrence of suicidal behavior or suicidal ideation were counted as having experienced suicidality. Suicidal behavior included suicide attempt, aborted attempt, interrupted attempt, or preparatory behavior. Suicidal ideation included a wish to die or active suicidal thought with or without method, intent or plan.</description>
          <population>APaT population, which consisted of all participants who received at least one dose of study drug.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="93"/>
                <count group_id="O6" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="5.6"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="4.2"/>
                    <measurement group_id="O5" value="2.2"/>
                    <measurement group_id="O6" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Total Epworth Sleepiness Scale (ESS) Score at Week 40</title>
        <description>The ESS is a self-administered questionnaire providing a measure of a person’s general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24 with a higher score indicating greater sleepiness.</description>
        <time_frame>Baseline and Week 40</time_frame>
        <population>Participants in the Full Analysis Set (FAS) population (all randomized participants who received at least one dose of study drug) that had a baseline value and data at Week 40 for Total ESS Score</population>
        <group_list>
          <group group_id="O1">
            <title>Preladenant 2 mg</title>
            <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Preladenant 5 mg</title>
            <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Preladenant 10 mg</title>
            <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Rasagiline 1 mg</title>
            <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
            <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Epworth Sleepiness Scale (ESS) Score at Week 40</title>
          <description>The ESS is a self-administered questionnaire providing a measure of a person’s general level of daytime sleepiness, or their average sleep propensity in daily life. The scale consists of 8 situations in which the participant rates their tendency to become sleepy on a scale of 0=no chance of dozing to 3=high chance of dozing. The overall score is the sum of the scores for the 8 situations for a minimum of 0 and a maximum of 24 with a higher score indicating greater sleepiness.</description>
          <population>Participants in the Full Analysis Set (FAS) population (all randomized participants who received at least one dose of study drug) that had a baseline value and data at Week 40 for Total ESS Score</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="3.4" lower_limit="-15.0" upper_limit="46.2"/>
                    <measurement group_id="O2" value="24.0" spread="3.9" lower_limit="7.8" upper_limit="40.3"/>
                    <measurement group_id="O3" value="22.5" lower_limit="-9.5" upper_limit="54.5"/>
                    <measurement group_id="O4" value="13.2" lower_limit="-5.9" upper_limit="32.4"/>
                    <measurement group_id="O5" value="8.3" lower_limit="-6.8" upper_limit="23.4"/>
                    <measurement group_id="O6" value="16.3" lower_limit="-3.3" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 42 weeks</time_frame>
      <desc>APaT population, which consisted of all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Preladenant 2 mg</title>
          <description>Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 2 mg in this extension study. Participants received preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Preladenant 5 mg</title>
          <description>Participant who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Preladenant 5 mg (on Placebo in Parent Study)</title>
          <description>Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 received preladenant 5 mg in this extension study. Participants received preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Preladenant 10 mg</title>
          <description>Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 continued to receive preladenant 10 mg in this extension study. Participants received preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Rasagiline 1 mg</title>
          <description>Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 continued to receive rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Rasagiline 1 mg (on Placebo in Parent Study)</title>
          <description>Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 received rasagiline 1 mg in this extension study. Participants received rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION GASTRIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ENCEPHALITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>NOSOCOMIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PERITONSILLAR ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>NEAR DROWNING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD SODIUM INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PATELLOFEMORAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>TORTICOLLIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>OVARIAN ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HYPOPERFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>THALAMIC INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>MENTAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PSYCHOTIC DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTITIS GLANDULARIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PULMONARY THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>RESPIRATORY PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>LYMPHOSTASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="215"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="96"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="93"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="218"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="218"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="215"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="218"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="215"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="218"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="215"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="218"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="215"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="218"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="215"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="215"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="96"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="93"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="218"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="215"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="218"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="215"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the Sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media, eg, any computer access system such as the Internet, World Wide Web, etc) that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early due to the lack of efficacy of preladenant in the parent studies NCT1155466 and NCT01227265.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

